培门冬酶(Pegaspargase)是治疗急性淋巴性白血病的注射药物[5] [6]。常与蒽环类药物长春新碱泼尼松并用[6]

培门冬酶
临床资料
读音/pəˈɡæspərɡz/
商品名英语Drug nomenclatureOncaspar
AHFS/Drugs.comMonograph
MedlinePlusa695031
核准状况
怀孕分级
  • : D
给药途径肌肉注射, 静脉注射
ATC码
法律规范状态
法律规范
识别信息
  • Pegylated E. coli L-asparagine amidohydrolase
CAS号130167-69-0  checkY
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
化学信息
化学式C1377H2208N382O442S17
摩尔质量31,732.06 g·mol−1

常见副作用包括过敏、血液凝固问题、高血糖、肝脏问题、胰腺炎和脑血栓[6]。孕期间使用可能对婴儿有害[7]。它是经过聚乙二醇化英语PEGylation门冬酰胺酶的改良版[8] [6]。作用机转是分解天门冬酰胺,降低它被用于制造蛋白质的可用性[6]

培门冬酶于 1994 年在美国取得医疗使用许可[6]。名列世界卫生组织基本药物标准清单[9]。是由西格玛-陶氏英语Leadiant Biosciences制造的[6]

参考文献

编辑
  1. ^ Prescription medicines: registration of new chemical entities in Australia, 2017. Therapeutic Goods Administration (TGA). 21 June 2022 [9 April 2023]. 
  2. ^ Prescription medicines and biologicals: TGA annual summary 2017. Therapeutic Goods Administration (TGA). 21 June 2022 [31 March 2024]. 
  3. ^ Cancer therapies. Health Canada. 8 May 2018 [13 April 2024]. 
  4. ^ Oncaspar EPAR. European Medicines Agency (EMA). [21 January 2021]. 
  5. ^ Graham ML. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 2003, 55 (10): 1293–302. PMID 14499708. doi:10.1016/S0169-409X(03)00110-8. 
  6. ^ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 Pegaspargase Monograph for Professionals. Drugs.com. [11 October 2019]. (原始内容存档于17 August 2019) (英语). 
  7. ^ Pegaspargase (Oncaspar) Use During Pregnancy. Drugs.com. [11 October 2019]. (原始内容存档于11 October 2019) (英语). 
  8. ^ UNM Cancer Center. [2007-08-28]. (原始内容存档于September 3, 2006). 
  9. ^ World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.